Fig. 6

No signs of immunotoxicity are observed in BrQ-treated mice. Normal 8-week-old C57BL/6 mice were administered orally with 200µL vehicle (0.5% CMC) or BrQ (3, 10, or 30 mg/kg/day) for 21 days. A Body weight was monitored every week. B, C Spleen samples were collected, pictured and weighed. D, E Leukocytes in the draining lymph node were isolated and stained for CD4⁺ T cells, CD8 + T cells, B cells (B220) and CD11b⁺ cells. Cell percentages were determined with flow cytometry analysis. F, G Cell surface staining results and statistic data of the CD4⁺ T cells, CD8⁺ T cells, B cells (B220) and CD11b⁺ cells in the blood. H, I Flow cytometric analysis and quantification of CD4⁺, CD8⁺, CD4⁻CD8⁻ (double negative, DN) and CD4⁺CD8⁺ (double positive, DP) in the thymus. Data are mean ± SEM of 5 mice per group versus vehicle group (one-way ANOVA). Representative data of two independent experiments